Navigation Links
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Date:6/3/2009

PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ --

- Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.

In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to receive GC in combination with the investigational agent BSI-201 or GC alone. Patients assigned to receive chemotherapy without BSI-201 were allowed to receive BSI-201 at the time of disease progression.

The primary study endpoint was the rate of clinical benefit, defined as complete or partial response or stable disease of at least 6 months. Secondary study endpoints included progression-free survival, overall survival and safety.

Approximately 62 percent of patients receiving BSI-201 in combination with GC showed clinical benefit, compared with 21 percent in the group receiving chemotherapy alone (p= 0.0002). Tumor response (complete or partial response) was observed in 48 percent of patients who received BSI-201 combined with chemotherapy, whereas patients receiving chemotherapy alone showed a response rate of 16 percent. Women who received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, respective
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
2. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
3. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
4. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
5. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
6. Premier Research Announces Milestone Investigational New Drug Application
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
9. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, ... the Office of Fair Trading (OFT) approval condition to the ... ViroPharma Incorporated (NASDAQ: VPHM).   As a result ... OFT approval, and Shire expects to complete the tender offer ... subject to the satisfaction of all of the remaining conditions ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 2011 PDI, Inc. (Nasdaq: PDII ), a ... companies, today announced the extension of a contract sales engagement ... began April 1 and will run for the balance of ... PDI of approximately $23 million. Under the program, ...
... April 4, 2011 VIVUS, Inc. (Nasdaq: VVUS ... the investigational drug QNEXA® for two years showed reductions in ... as improvements in lipid levels following significant reductions in weight ... two years. The data – additional results ...
Cached Medicine Technology:PDI Announces Contract Extension With Revenue Value of Approximately $23 Million 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:4/14/2014)... the scientific marvels of the 20th century, is currently ... bacterial infections. But scientists at the University of South ... its combat effectiveness, even against so-called "superbugs." , Bacteria ... penicillin family of drugs since their first wide-scale use ... infection, brought about by the bacterium Staphylococcus aureus ...
(Date:4/14/2014)... information on colorectal cancer is too difficult for most ... risks to and concerns of patients, a study by ... review of a dozen popular websites, most of the ... written beyond the recommended sixth-grade reading level, while content ... well as the barriers to and benefits of screening, ...
(Date:4/14/2014)... SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced ... antibody prevents the destruction of human red blood ... a type of autoimmune hemolytic anemia (AIHA). The ... protease C1s, prevents complement activation induced by cold ... the journal Blood earlier this month. ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... about health that aren,t based on medical evidence are ... research suggests. , In the Ohio State University study, ... as "irrational health beliefs" on a standard measure of ... a prescribed cardiac rehab program. , Among the ... flu vaccine or believing, based on family history alone, ...
Breaking Medicine News(10 mins):Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... Kashmir University Wednesday suspended construction of a guesthouse inside the ... following student protests . ,Vice Chancellor Abdul Wahid ... campus here. ,Hundreds of students had launched an ... chinar trees being felled to make way for the construction. ...
... peoples sleep. Some are light sleepers, whereas others sleep ... their time . ,Such sleeping pattern ... circumstances, habits, and other non-biological factors. But now a ... and assistant director of the Sleep and Performance Research ...
... The international HIV and AIDS charity AVERT is today launching ... end to the 380,000 child AIDS deaths and half ... year. ,At this year's G8 summit in Germany, the ... chance to stop child AIDS deaths by committingspecific funds for ...
... breast Cancer treatment comes in the form of Intraoperative ... radiation during surgery . Thus the patient can avoid ... the Princess Margaret Hospital team combined the expertise of ... and nurses to perform its first procedure. It marked ...
... today seems to be disintegrating at an alarming rate. Studies ... one in ten children now has a mental health disorder ... More than a million children have mental health problems, a ... conduct disorders have become twice as common since the 1930s ...
... The Canadian Food Inspection Agency has issued a warning to ... Alberta, Ontario, Quebec and Nova Scotia as it could ... the product has been done by Les Aliments G. Dion. ... the market. ,Salmonella contaminated food does not appear ...
Cached Medicine News:Health News:Individual Differences in Sleep Structure are Biologically Determined 2Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Intraoperative Radiation Therapy a New Step in Breast Cancer Treatment 2Health News:Mental Health of Children on the Decline 2
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: